BOSTON—Amy Elazzouzi, Vice President of Finance at Aura Biosciences , Inc. (NASDAQ:AURA), recently sold 1,001 shares of the company's common stock. The shares were sold at a weighted average price of $7.6715, totaling approximately $7,679. The transaction comes as AURA trades at $7.93, with analysts setting an average price target of $20-23, suggesting significant upside potential according to InvestingPro data. This transaction was executed to cover tax withholding obligations related to the vesting of restricted stock units. Following this sale, Elazzouzi holds 38,442 shares directly. The sale was conducted automatically, not at Elazzouzi's discretion, as part of a pre-arranged plan. Aura Biosciences, a Boston-based biotechnology company valued at $388 million, maintains a strong liquidity position with a current ratio of 12.47 and more cash than debt on its balance sheet. InvestingPro analysis reveals 6 additional key insights about AURA's financial health and growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.